For healthcare professionals only


Adjuvant trastuzumab for breast cancer: The other side of the coin

BMJ 2005; 331 doi: (Published 17 November 2005) Cite this as: BMJ 2005;331:1202
  1. Somasundari Gopalakrishnan (, honorary fellow,
  2. John Linnane, deputy director of public health
  1. Walsall Teaching Primary Care Trust, Walsall WS1 1TE

    EDITOR—The editorial by Dent and Clemons in the middle of media frenzy about the use of trastuzumab was appropriate.1 As suggested, equity of access to such novel and expensive treatments should be through well designed funding processes. In calculating the cost of treatment, the overall cost of the drug, its …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription